[Amyloidosis: state of the art].
Amyloidosis is characterized by a heterogeneous group of diseases due to deposition of a fibrillar, proteinaceous material, in different tissues. In this review pathogenetic mechanisms, clinical and therapeutic findings of the most important aspects of the disease, are described.
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000682:Amyloid / Q000032:analysis; D000686:Amyloidosis / Q000175:diagnosis / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use; D008875:Middle Aged; D010956:Plasmapheresis; D011379:Prognosis; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein / Q000032:analysis; D000683:Serum Amyloid P-Component / Q000032:analysis
D000305:Adrenal Cortex Hormones; D000682:Amyloid; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein; D000683:Serum Amyloid P-Component; D001379:Azathioprine; D003078:Colchicine; D004121:Dimethyl Sulfoxide
Amiloidosi: lo stato dell'arte.